IQVIA Holdings Inc. (0JDM.L)
USD 157.19
(-6.74%)
USD 157.19
(-6.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.68 Billion USD | 5.3% |
| 2022 | 25.33 Billion USD | 2.62% |
| 2021 | 24.68 Billion USD | 0.51% |
| 2020 | 24.56 Billion USD | 5.65% |
| 2019 | 23.25 Billion USD | 3.11% |
| 2018 | 22.54 Billion USD | -0.85% |
| 2017 | 22.74 Billion USD | 7.23% |
| 2016 | 21.2 Billion USD | 440.15% |
| 2015 | 3.92 Billion USD | 18.77% |
| 2014 | 3.3 Billion USD | 7.79% |
| 2013 | 3.06 Billion USD | 22.71% |
| 2012 | 2.49 Billion USD | 7.59% |
| 2011 | 2.32 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 26.57 Billion USD | -0.4% |
| 2024 Q3 | 27.18 Billion USD | 2.96% |
| 2024 Q2 | 26.39 Billion USD | -0.66% |
| 2023 Q2 | 26.03 Billion USD | 1.15% |
| 2023 Q4 | 26.68 Billion USD | 2.71% |
| 2023 FY | 26.68 Billion USD | 5.3% |
| 2023 Q3 | 25.97 Billion USD | -0.23% |
| 2023 Q1 | 25.73 Billion USD | 1.59% |
| 2022 FY | 25.33 Billion USD | 2.62% |
| 2022 Q3 | 24.22 Billion USD | -0.78% |
| 2022 Q1 | 24.96 Billion USD | 1.13% |
| 2022 Q2 | 24.41 Billion USD | -2.23% |
| 2022 Q4 | 25.33 Billion USD | 4.6% |
| 2021 Q1 | 24.46 Billion USD | -0.39% |
| 2021 FY | 24.68 Billion USD | 0.51% |
| 2021 Q2 | 23.93 Billion USD | -2.17% |
| 2021 Q4 | 24.68 Billion USD | 2.73% |
| 2021 Q3 | 24.03 Billion USD | 0.4% |
| 2020 Q3 | 23.83 Billion USD | 2.82% |
| 2020 Q4 | 24.56 Billion USD | 3.05% |
| 2020 Q1 | 23.07 Billion USD | -0.74% |
| 2020 Q2 | 23.18 Billion USD | 0.45% |
| 2020 FY | 24.56 Billion USD | 5.65% |
| 2019 Q4 | 23.25 Billion USD | 1.57% |
| 2019 Q3 | 22.89 Billion USD | -0.76% |
| 2019 Q2 | 23.06 Billion USD | -0.18% |
| 2019 Q1 | 23.1 Billion USD | 2.48% |
| 2019 FY | 23.25 Billion USD | 3.11% |
| 2018 Q1 | 23.23 Billion USD | 2.17% |
| 2018 FY | 22.54 Billion USD | -0.85% |
| 2018 Q4 | 22.54 Billion USD | 0.23% |
| 2018 Q3 | 22.49 Billion USD | -0.57% |
| 2018 Q2 | 22.62 Billion USD | -2.62% |
| 2017 FY | 22.74 Billion USD | 7.23% |
| 2017 Q1 | 21.18 Billion USD | -0.12% |
| 2017 Q3 | 22.44 Billion USD | 3.04% |
| 2017 Q4 | 22.74 Billion USD | 1.32% |
| 2017 Q2 | 21.78 Billion USD | 2.83% |
| 2016 Q1 | 3.98 Billion USD | 1.44% |
| 2016 FY | 21.2 Billion USD | 440.15% |
| 2016 Q4 | 21.2 Billion USD | 413.66% |
| 2016 Q3 | 4.12 Billion USD | 4.19% |
| 2016 Q2 | 3.96 Billion USD | -0.51% |
| 2015 Q2 | 3.34 Billion USD | 3.25% |
| 2015 Q1 | 3.23 Billion USD | -2.09% |
| 2015 FY | 3.92 Billion USD | 18.77% |
| 2015 Q4 | 3.92 Billion USD | -2.66% |
| 2015 Q3 | 4.03 Billion USD | 20.71% |
| 2014 Q4 | 3.3 Billion USD | 6.41% |
| 2014 Q2 | 2.97 Billion USD | -2.72% |
| 2014 Q1 | 3.06 Billion USD | -0.16% |
| 2014 FY | 3.3 Billion USD | 7.79% |
| 2014 Q3 | 3.1 Billion USD | 4.3% |
| 2013 Q1 | 2.42 Billion USD | -2.9% |
| 2013 Q2 | 2.64 Billion USD | 9.13% |
| 2013 Q3 | 2.84 Billion USD | 7.32% |
| 2013 FY | 3.06 Billion USD | 22.71% |
| 2013 Q4 | 3.06 Billion USD | 7.91% |
| 2012 FY | 2.49 Billion USD | 7.59% |
| 2012 Q4 | 2.49 Billion USD | 0.0% |
| 2011 FY | 2.32 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -3108.05% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -2747.133% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -3329.963% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -16021.061% |
| bluebird bio, Inc. | 619.16 Million USD | -4209.218% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -21101.646% |
| Imunon, Inc. | 21.91 Million USD | -121630.614% |
| Editas Medicine, Inc. | 499.15 Million USD | -5245.255% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -695.129% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -2125.828% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -720.6% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -1793.643% |
| Verastem, Inc. | 149.71 Million USD | -17720.837% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 67.076% |
| Waters Corporation | 4.62 Billion USD | -476.655% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 72.975% |
| Biogen Inc. | 26.84 Billion USD | 0.61% |
| Nektar Therapeutics | 398.03 Million USD | -6603.213% |
| Perrigo Company plc | 10.8 Billion USD | -146.838% |
| Dynavax Technologies Corporation | 997.09 Million USD | -2575.871% |
| Illumina, Inc. | 10.11 Billion USD | -163.881% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -94271.212% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -3319.102% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -11891.137% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -40516.532% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -289.982% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -16039.003% |
| Evolus, Inc. | 188.99 Million USD | -14017.081% |
| Adicet Bio, Inc. | 207.29 Million USD | -12771.029% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -13415.868% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 19.345% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -12864.781% |
| FibroGen, Inc. | 423.52 Million USD | -6199.687% |
| Agilent Technologies, Inc. | 10.76 Billion USD | -147.896% |
| OPKO Health, Inc. | 2.01 Billion USD | -1226.293% |
| Homology Medicines, Inc. | 47.05 Million USD | -56599.322% |
| Geron Corporation | 394.07 Million USD | -6670.521% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -596.654% |
| Exelixis, Inc. | 2.94 Billion USD | -806.79% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -7140.631% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -17182.007% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -1950.843% |
| Zoetis Inc. | 14.28 Billion USD | -86.763% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -4435.765% |
| Abeona Therapeutics Inc. | 64 Million USD | -41587.76% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | -17.381% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -47588.073% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -792.32% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -717.288% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -4192.883% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -1439.345% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -2442.864% |
| Insmed Incorporated | 1.32 Billion USD | -1906.336% |
| TG Therapeutics, Inc. | 329.58 Million USD | -7995.283% |
| Incyte Corporation | 6.78 Billion USD | -293.403% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -1354.085% |